Apart from a known individual variability in the course of MS, these differences may result from distinctive inclusion criteria—we analysed patients treated with IFN-β only, whereas in the cited study patients treated with various drugs were included23. This evidence concerns the gene IFNB1 and myeloid sarcoma.